H.C. Wainwright lowered the firm’s price target on Aslan Pharmaceuticals to $4.50 from $7 and keeps a Buy rating on the shares. The analyst cites the private placement for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASLN:
- Aslan Pharmaceuticals announces $20M private placement
- ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
- ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
- Aslan, Thermo Fisher announce partnership for manufacturing eblasakimab